Definium Therapeutics, Inc. (DFTX)

Definium Therapeutics, Inc. (DFTX) is a healthcare company (biotechnology) based in the United States. The share price is $29.26, down 2.98% on the day, which values the company at $4.01B. Price as of 17 Nov 2026, 17:15 UTC, from Yahoo Finance.

Key facts

Share price
$29.26−2.98% today
Market value
$4.01B
200-week average
$11.77149% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Definium Therapeutics, Inc. in more detail

DFTX trades at -15.7× next year's expected earnings. It sits 149% above its 200-week average of $11.77.

In its favour: More cash than debt. Worth checking: Weak Piotroski score; Share count keeps rising.

2 of the superinvestors tracked here hold DFTX, including Peter Kolchinsky (0.6% of the portfolio), Stanley Druckenmiller (0.4% of the portfolio).

Superinvestors holding DFTX

2 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:DFTX vs LEGN (Definium Therapeutics, Inc. vs Legend Biotech)DFTX vs OPCH (Definium Therapeutics, Inc. vs Option Care Health)DFTX vs TVTX (Definium Therapeutics, Inc. vs Travere Therapeutics)DFTX vs CRSP (Definium Therapeutics, Inc. vs CRISPR Therapeutics)DFTX vs HTFL (Definium Therapeutics, Inc. vs Heartflow)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

Definium Therapeutics, Inc. (DFTX): questions and answers

What is Definium Therapeutics, Inc.'s market cap?

Definium Therapeutics, Inc. is valued at $4.01B at a share price of $29.26.

Is DFTX above its 200-week moving average?

Yes. DFTX is 148.5% above its 200-week average of $11.77. Long-term investors watch that line because strong companies rarely trade below it for long.

Does DFTX pay a dividend?

Definium Therapeutics, Inc. does not currently pay a regular dividend.

Which famous investors own DFTX?

In their latest quarterly filings, Peter Kolchinsky (0.6% of the portfolio), Stanley Druckenmiller (0.4% of the portfolio) hold DFTX. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Definium Therapeutics, Inc. (DFTX) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/DFTX

Underlying data: Yahoo Finance; company filings with the SEC.